• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MEMANTINE Drug Record

  • Summary
  • Interactions
  • Claims
  • MEMANTINE chembl:CHEMBL807 Approved

    Alternate Names:

    MEMANTINE
    D-145
    DRG-0267
    NAMENDA
    MEMANTINA
    1,3-DIMETHYL-5-ADAMANTANAMINE
    1-AMINO-3,5-DIMETHYLADAMANTANE
    MEMANTINUM
    3,5-DIMETHYL-1-AMINOADAMANTANE
    NAMENDA®
    3,5-DIMETHYL-1-ADAMANTANAMINE
    1,3-DIMETHYLAMINOADAMANTANE
    3,5-DIMETHYLTRICYCLO(3.3.1.1(3,7))DECAN-1-AMINE
    chemidplus:19982-08-2
    pubchem.compound:4054
    rxcui:6719
    chembl:CHEMBL807
    drugbank:01043

    Drug Info:

    Drug Class antiparkinson agents
    Year of Approval 2003
    Drug Indications for treatment of Alzheimer's disease
    FDA Approval approved
    Drug Indications for treatment of glaucoma
    Drug Class Small Molecule
    (2 More Sources)

    Publications:

    Smothers et al., 2007, Pharmacological characterization of glycine-activated currents in HEK 293 cells expressing N-methyl-D-aspartate NR1 and NR3 subunits., J. Pharmacol. Exp. Ther.
    Rogawski et al., 2003, The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease., CNS Drug Rev
    Schrattenholz et al., 2006, NMDA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling., Curr Top Med Chem
    Chatterton et al., 2002, Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits., Nature
    Foster et al., 2006, Glutamate- and GABA-based CNS therapeutics., Curr Opin Pharmacol
    Rook Y et al., 2010, Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents., J Med Chem
    Kotermanski et al., 2009, Memantine binding to a superficial site on NMDA receptors contributes to partial trapping., J. Physiol. (Lond.)
    Cacabelos R et al., 1999, The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease., Int J Geriatr Psychiatry
    Robinson DM et al., 2006, Memantine: a review of its use in Alzheimer's disease., Drugs
    Chen et al., 2005, Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels., J. Pharmacol. Exp. Ther.
    Blanpied et al., 1997, Trapping channel block of NMDA-activated responses by amantadine and memantine., J. Neurophysiol.
    Maler et al., 2005, Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons., Brain Res.
    Bresink et al., 1996, Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells., Br. J. Pharmacol.
    Nakazato et al., 2005, Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model., Pharmacology
    Kashiwagi et al., 2002, Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore., Mol. Pharmacol.
    Noetzli M et al., 2013, Population pharmacokinetic study of memantine: effects of clinical and genetic factors., Clin Pharmacokinet
  • MEMANTINE   GRIN2A

    Interaction Score: 3.3

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    20361801 15901795 14530799 9120573 16009352 8886398


    Sources:
    DTC TEND

  • MEMANTINE   GRIN3A

    Interaction Score: 2.89

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Namenda
    Novel drug target Established target
    Trial Name memantine

    PMIDs:
    17502428 14530799 16719808 11823786 16377242


    Sources:
    TdgClinicalTrial TEND

  • MEMANTINE   GRIN2B

    Interaction Score: 2.28

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name memantine
    Novel drug target Established target
    Trial Name Namenda

    PMIDs:
    14530799 15452358 16009352 9120573 11854433


    Sources:
    TdgClinicalTrial TEND

  • MEMANTINE   GRIN1

    Interaction Score: 2.11

    Interaction Types & Directionality:
    binder
    antagonist (inhibitory)

    Interaction Info:
    Trial Name memantine
    Novel drug target Established target
    Trial Name Namenda

    PMIDs:
    20361801 19687120 10029935 16906789 14530799


    Sources:
    DTC TdgClinicalTrial

  • MEMANTINE   NR1I2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23371894


    Sources:
    PharmGKB

  • TEND: MEMANTINE

    • Version: 01-August-2011

    Alternate Names:
    MEMANTINE Primary Drug Name

    Drug Info:
    Year of Approval 2003
    Drug Class antiparkinson agents

    Publications:

  • TdgClinicalTrial: MEMANTINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Class Small Molecule
    Drug Indications for treatment of glaucoma
    FDA Approval approved

    Publications:

  • DTC: MEMANTINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL807 ChEMBL Drug ID

    Drug Info:

    Publications:
    Rook Y et al., 2010, Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents., J Med Chem

  • PharmGKB: memantine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Noetzli M et al., 2013, Population pharmacokinetic study of memantine: effects of clinical and genetic factors., Clin Pharmacokinet

  • TTD: Memantine

    • Version: 2020.06.01

    Alternate Names:
    D01JEU TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL807

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21